Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 10/20 | 0.54 |
| ▸ | JAK3 | P52333 | 10/20 | 0.54 |
| ▸ | JAK1 | P23458 | 5/20 | 0.54 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.51 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.51 |
| ▸ | FGFR3 | P22607 | 3/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | BTK | Q06187 | 4/20 | 0.47 |
| ▸ | TYK2 | P29597 | 1/20 | 0.47 |
| ▸ | CDC7 | O00311 | 1/20 | 0.46 |
| ▸ | PLK4 | O00444 | 1/20 | 0.46 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.46 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.46 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.46 |
| ▸ | INSR | P06213 | 1/20 | 0.46 |
| ▸ | LCK | P06239 | 1/20 | 0.46 |
| ▸ | FYN | P06241 | 1/20 | 0.46 |
| ▸ | CDK1 | P06493 | 1/20 | 0.46 |
| ▸ | RET | P07949 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23150464 | 0.93 | JAK3 (0.59) | JAK2JAK3JAK1FGFR1FGFR2 | |
| SCHEMBL23150425 | 0.91 | JAK2 (0.49) | JAK2JAK3JAK1FGFR1FGFR2 | |
| SCHEMBL17267555 | 0.88 | JAK2 (0.70) | JAK2JAK3JAK1FGFR1FGFR2 | |
| SCHEMBL17267691 | 0.85 | TGFBR1 (0.64) | JAK2JAK3JAK1FGFR1FGFR2 | |
| SCHEMBL31046956 | 0.85 | TGFBR1 (0.64) | JAK2JAK3JAK1FGFR1FGFR2 | |
| SCHEMBL17267749 | 0.83 | JAK2 (0.78) | JAK2JAK3JAK1FGFR1FGFR2 | |
| SCHEMBL17936187 | 0.83 | KCNH2 (0.50) | JAK2JAK3JAK1FGFR1FGFR2 | |
| SCHEMBL30405165 | 0.83 | FGFR1 (0.49) | JAK2JAK3JAK1FGFR1FGFR2 | |
| SCHEMBL17267688 | 0.82 | JAK2 (0.79) | JAK2JAK3JAK1FGFR1FGFR2 | |
| SCHEMBL25334338 | 0.81 | JAK2 (0.67) | JAK2JAK3JAK1FGFR2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112368289-B | C26-linked rapamycin analogues as MTOR inhibitors | 锐新医药公司 | 2024-02-20 | — | — | CN | disclosed |
| CN-115916194-A | Methods for delaying, preventing and treating acquired resistance to RAS inhibitors | 锐新医药公司 | 2023-04-04 | — | — | CN | disclosed |
| CN-112771054-A | C40-, C28-and C-32-linked rapamycin analogs as mTOR inhibitors | 锐新医药公司 | 2021-05-07 | — | — | CN | disclosed |
| US-20210094975-A1 | RAPAMYCIN ANALOGS AS MTOR INHIBITORS | Revolution Medicines, Inc. | 2021-04-01 | — | — | US | disclosed |
| CN-112368289-A | C26-linked rapamycin analogs as MTOR inhibitors | 锐新医药公司 | 2021-02-12 | — | — | CN | disclosed |
| CN-110770243-A | Rapamycin analogs as MTOR inhibitors | 锐新医药公司 | 2020-02-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210094975-A1 | RAPAMYCIN ANALOGS AS MTOR INHIBITORS | MTOR, RICTOR, RPTOR | JAK2 445/4885JAK3 2053/4885JAK1 1747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.